

COUGHLIN DUFFY LLP  
350 Mount Kemble Avenue  
P.O. Box 1917  
Morristown, New Jersey 07962-1917  
(973) 267-0058  
*Attorneys for Defendants AstraZeneca Pharmaceuticals LP,  
AstraZeneca LP, Astra USA, Inc., KBI Sub Inc., and Zeneca Inc.*

---

LARRY BOLDEN,	:	SUPERIOR COURT OF NEW JERSEY
	:	LAW DIVISION: MIDDLESEX COUNTY
Plaintiff,	:	
	:	DOCKET NO. MID-L-390-07-MT
v.	:	
	:	CIVIL ACTION
ASTRAZENECA	:	
PHARMACEUTICALS LP, et al.,	:	In Re Risperdal/Seroquel/Zyprexa Litigation
	:	Case No. 274
Defendants.	:	
	:	<b>ORDER OF DISMISSAL WITH PREJUDICE</b>
	:	
	:	<b>RETURN DATE: <u>January 4, 2008</u></b>


---

**THIS MATTER** having been brought before the Court by Coughlin Duffy LLP, attorneys for Defendants AstraZeneca Pharmaceuticals LP, AstraZeneca LP, Astra USA, Inc., KBI Sub Inc., and Zeneca Inc. (collectively "AstraZeneca") to dismiss plaintiff's Amended Complaint with prejudice for failure to serve a Short Form Plaintiff Fact Sheet pursuant to Case Management Order No. 4 ("CMO 4"), § II.E.; such dismissal with prejudice being authorized by CMO 4, § II.H; the Court having considered the papers submitted and having heard the arguments of counsel at the October 10, 2007, Case Management Conference; the Court having granted plaintiff eighty-five (85) additional days, or until January 4, 2008, to serve a Short Form Plaintiff Fact Sheet; and plaintiff having failed to serve a Short Form Plaintiff Fact Sheet by January 4, 2008; and for good cause shown;

IT IS on this 7<sup>th</sup> day of January, 2008;

**ORDERED** that AstraZeneca's motion is hereby **GRANTED** and that plaintiff's Amended Complaint is **DISMISSED WITH PREJUDICE** pursuant to CMO 4, § II.H.; and it is further

**ORDERED** that a signed copy of this Order be served on all counsel within seven (7) days of the date hereof.

  
\_\_\_\_\_  
Jamie D. Happas, J.S.C.

Unopposed  
 Opposed

**FILED**

**JAN 07 2008**

Judge Jamie D. Happas

Having reviewed the above motion, I find it to be meritorious on its face and is unopposed. Pursuant to R.1:6-2, it therefore will be granted essentially for the reasons set forth in the moving papers.